Please login to the form below

Not currently logged in
Email:
Password:

multiple sclerosis

This page shows the latest multiple sclerosis news and features for those working in and with pharma, biotech and healthcare.

Hemlibra off to a flyer as Roche raises 2019 forecasts

Hemlibra off to a flyer as Roche raises 2019 forecasts

However, new drugs including Ocrevus (ocrelizumab) for multiple sclerosis, cancer immunotherapy Tecentriq (atezolizumab) and new haemophilia drug Hemlibra (emicizumab) acted as a buffer.

Latest news

More from news
Approximately 75 fully matching, plus 455 partially matching documents found.

Latest Intelligence

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    4. Mayzent – a latest addition to competitive MS market. Novartis’ Mayzent (siponimod) is expected to be launched in the US in Q1 for multiple sclerosis, with an EU launch to follow ... EvaluatePharma has predicted it could become a nearly $2.5bn

  • Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available? Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?

    In the past, specialised infusion centres have been established to provide outpatient infusion therapy administered by nurses to multiple sclerosis patients in Germany.

  • New models of NHS care – new models of pharma response? New models of NHS care – new models of pharma response?

    The Accelerated Access Collaborative. Ewan Barbour, Market Access and Pricing Director, Merck, presented on its multiple sclerosis treatment Mavenclad being selected to be among the first designated Rapid Uptake products on

  • Pharma: in search of the sustainable ‘win win’ with the NHS Pharma: in search of the sustainable ‘win win’ with the NHS

    Even with the drive towards Integrated Cares Systems (ICSs) across England, the reality is that the industry will still have to deal with multiple, independent NHS organisations when negotiating a joint ... The company has just secured 'Rapid Uptake'

  • Tackling a formidable foe Tackling a formidable foe

    Ali Frederic Ben-Amor tells how Merck is taking the fight to multiple sclerosis. " />. ... It is easy to get the impression that the quest for advanced multiple sclerosis treatments, and eventually a cure, is on cruise control.

More from intelligence
Approximately 0 fully matching, plus 28 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 24 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 10 fully matching, plus 24 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
AMICULUM Limited

AMICULUM® is an independent global healthcare communications, consulting and learning business with a global team of >220 healthcare communications professionals,...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics